Sangamo Therapeutics, Inc. (NASDAQ:SGMO)went down by -0.74% from its latest closing price when compared to the 1-year high value of $13.91 and move down -48.93%, while SGMO stocks collected -4.50% of loss with the last five trading sessions. Press Release reported 7 hours ago that Sangamo Therapeutics Announces Participation at the Jefferies 2019 London Healthcare Conference
Sangamo Therapeutics, Inc. (NASDAQ:SGMO) Worth an Investment?
Sangamo Therapeutics, Inc. (NASDAQ: SGMO) The 36 Months beta value for SGMO stocks is at 2.79, while of the analysts out of 0 who provided ratings for Sangamo Therapeutics, Inc. stocks as a “buy” while as overweight, rated it as hold and as sell. The average price we get from analysts is $22.00 which is $11.33 above current price. SGMO currently has a short float of 14.50% and public float of 115.83M with average trading volume of 1.11M shares.
SGMO Market Performance
SGMO stocks went down by -4.50% for the week, with the monthly jump of 12.33% and a quarterly performance of -18.85%, while its annual performance rate touched -9.85%. The simple moving average for the period of the last 20 days is 0.94% for SGMO stocks with the simple moving average of -9.34% for the last 200 days.
Analysts’ Opinion on Sangamo Therapeutics, Inc. (NASDAQ:SGMO)
Many brokerage firms have already submitted their reports for SGMO stocks, with H.C. Wainwright repeating the rating for SGMO shares by setting it to “Buy”. The predicted price for SGMO socks in the upcoming period according to H.C. Wainwright is $16 based on the research report published on August 26, 2019.
JP Morgan, on the other hand, stated in their research note that they expect to see SGMO stock at the price of $16. The rating they have provided for SGMO stocks is “Neutral” according to the report published on November 14, 2018.
Guggenheim gave “ Neutral” rating to SGMO stocks, setting the target price at $16 in the report published on November 9, 2018.
SGMO Stocks -0.62% Far from 50 Day Moving Average
After a stumble in the market that brought SGMO to its low price for the period of the last 52 weeks, Sangamo Therapeutics, Inc. was unable to take a rebound, for now settling with -32.85% of loss for the given period.
The stock volatility was left at 4.49%, however, within the period of a single month, the volatility rate increased by 3.62%, while the shares surge at the distance of +10.27% for the moving average in the last 20 days. In oppose to the moving average for the last 50 days, trading by -10.11% lower at the present time.
In the course of the last 5 trading sessions, SGMO went down by -4.50%, which changed the moving average for the period of 200 days to the total of -24.07% of losses for the stock in comparison to the 20-day moving average settled at $9.30. In addition, Sangamo Therapeutics, Inc. saw -18.64% in overturn over the period of a single year with a tendency to cut further losses.
SGMO Stock Insider Trading
Reports are indicating that there were more than several insider trading activities at Sangamo Therapeutics, Inc. (SGMO), starting from Yi Kathy, who sold 5,000 shares at the price of $10.00 back on May 15. After this action, Rushing now owns 25,512 shares of Sangamo Therapeutics, Inc., valued at $50,000 with the latest closing price.
Yi Kathy, the EVP & Chief Financial Officer of Sangamo Therapeutics, Inc., sold 5,000 shares at the value of $12.11 during a trade that took place back on Apr 15, which means that Yi Kathy is holding 25,512 shares at the value of $60,550 based on the most recent closing price.
SGMO Stock Fundamentals
The current profitability levels are settled at -88.87 for the present operating margin. The net margin for Sangamo Therapeutics, Inc. stands at -80.91. Total capital return value is set at -24.70, while invested capital returns managed to touch -22.52. Equity return holds the value -30.40%, with -19.40% for asset returns.
Based on Sangamo Therapeutics, Inc. (SGMO), the company’s capital structure generated 7.55 points for debt to equity in total, while total debt to capital is set at the value of 7.02.
The value for Enterprise to Sales is 9.66 with debt to enterprise value settled at 0.04. The receivables turnover for Sangamo Therapeutics, Inc. is 19.57 with the total asset turnover at the value of 0.19. The liquidity ratio also appears to be rather interesting for investors as it stands at 5.23.